Catalent (NYSE:CTLT) Price Target Raised to $63.00 at Barclays

Catalent (NYSE:CTLT) had its price target increased by Barclays from $47.00 to $63.00 in a research report report published on Friday, Benzinga reports. Barclays currently has an equal weight rating on the stock.

CTLT has been the topic of a number of other research reports. Stephens restated an equal weight rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. StockNews.com began coverage on Catalent in a research note on Saturday, June 22nd. They issued a sell rating for the company. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Catalent presently has a consensus rating of Hold and a consensus price target of $55.65.

Catalent Stock Down 0.3 %

Shares of NYSE:CTLT opened at $56.23 on Friday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. Catalent has a 52-week low of $31.80 and a 52-week high of $60.20. The business’s 50 day simple moving average is $55.56 and its two-hundred day simple moving average is $53.74. The firm has a market cap of $10.18 billion, a P/E ratio of -9.22, a PEG ratio of 10.69 and a beta of 1.20.

Catalent (NYSE:CTLT) last issued its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. As a group, research analysts forecast that Catalent will post -0.17 EPS for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the sale, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.31% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Lindbrook Capital LLC grew its position in shares of Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares in the last quarter. Gladius Capital Management LP bought a new stake in shares of Catalent during the third quarter valued at about $28,000. GAMMA Investing LLC bought a new stake in shares of Catalent during the fourth quarter valued at about $33,000. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Catalent by 1,162.3% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after buying an additional 709 shares in the last quarter. Finally, Rakuten Securities Inc. bought a new position in shares of Catalent in the fourth quarter valued at approximately $46,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.